Project Grant R21HD116039

Award Date 9/17/24
Completion Date 8/31/26
Dollars Obligated $450K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $774,229 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Kaiser Foundation Hospitals in Oakland, CA. The grant, titled "Understanding the Impact of Early Life Factors on Cardiometabolic Risk Throughout the Life Course in a Large and Diverse Cohort of Adolescents and Young Adults", aims to conduct a large longitudinal cohort study to better understand the epidemiology of cardiometabolic outcomes...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $720,399 to the University of Colorado-Denver to conduct research on the impact of pregnancy microbiomes on maternal and child cardiovascular health in a racially and ethnically diverse population. The key objectives are to: 1) Characterize the distinct body-site specific microbiomes (oral, gut, vaginal) and metabolomes of pregnant individuals, and...
This federal Project Grant award of $732,261 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on leveraging large-scale, multi-ethnic, multi-omic data to conduct functional analysis of genetic loci associated with central obesity. The primary objectives are to identify expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs) using data from nine longitudinal studies in the...
The federal Project Grant award of $234,000.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to investigate "Immunometabolic Dysregulations in the Offspring of Obese Mothers". The project, awarded to Oregon Health & Science University, aims to study the increased risk of obesity and metabolic disease in newborns of obese...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Duke University a $241,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to study the regulation of metabolic diseases by the human commensal bacterium Clostridium immunis. The overarching goal is to determine the mechanism by which an exopolysaccharide (EPS) secreted by C. immunis decreases visceral adiposity, a key risk factor for type 2 diabetes and...
This federal Project Grant award of $777,954 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a mixed-method study to construct a school-based adolescent preconception cohort, engage adolescents and stakeholders to develop acceptable school-based policy solutions, and utilize agent-based modeling to capture school system dynamics. The overarching goal is to intervene on preconception cardiovascular health and address maternal health...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to define the mechanistic drivers of impaired B cell response to influenza A virus vaccine under conditions of obesity. The total funding amount is $148,880, awarded on November 1, 2025, with an ultimate completion date of June 30, 2027. The research will be conducted by St. Jude Children's Research Hospital Inc. to uncover defects...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, will provide $821,087 to Emory University to study the relationship between latent tuberculosis infection (LTBI) and the risk of developing diabetes mellitus and cardiovascular disease. The key objectives are to: Estimate the relationship between LTBI and indicators of diabetes and cardiovascular disease; Determine if established DNA...
The U.S. National Institutes of Health (NIH) awarded a $1,282,030 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Yale University to conduct a pilot randomized trial titled "Addressing Social Determinants of Health in Young Adults with Type 1 Diabetes through Comprehensive Assessment, Responsiveness, and Engagement (T1CARE)." The project aims to test the feasibility and preliminary efficacy of a personalized intervention to address the social and clinical...
The Project Grant, awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund a study to investigate how maternal hyperglycemia impacts embryonic metabolism and development in the C. elegans model. The $474,878 award will enable researchers at Childrens Hospital Medical Center to generate single-cell resolution data on metabolic changes during embryonic...

INTER-GENERATIONAL CARDIOMETABOLIC RISK: EXPLORE UNDERLYING IMMUNE PATHWAYS - ABSTRACT DESPITE DECADES OF CONCERTED EFFORTS, THE PREVALENCE OF OBESITY AND ITS ASSOCIATED MORBIDITIES SUCH AS TYPE 2 DIABETES (T2D) AND CARDIOVASCULAR DISEASES (CVD) CONTINUE TO CLIMB IN THE US AND RACIAL AND ETHNIC MINORITY POPULATIONS LIVING IN LOW-INCOME HOUSEHOLDS AND COMMUNITIES ARE DISPROPORTIONALLY AFFECTED. PART OF THE REASON IS A WELL-OBSERVED VICIOUS CYCLE OF INTERGENERATIONAL AMPLIFICATION. HOWEVER, THE UNDERLYING PATHWAYS DRIVING THIS CYCLE REMAIN POORLY UNDERSTOOD. THIS PROPOSAL AIMS TO EXPLORE A NOVEL HYPOTHESIS REGARDING THE ROLE OF CLINICAL AND SUBCLINICAL INFECTION AND RESULTING INFLAMMATION IN THE INTERGENERATIONAL CARDIOMETABOLIC LINK. THE PROPOSED STUDY IS MOTIVATED BY A STRONG SCIENTIFIC PREMISE. FIRST, GROWING EVIDENCE GENERATED BY US AND OTHERS DEMONSTRATED THAT MATERNAL CARDIOMETABOLIC CONDITIONS CONTRIBUTE TO CHILD CARDIOMETABOLIC RISKS. THIS INTERGENERATIONAL LINK MAY ORIGINATE IN UTERO AND AMPLIFY THE CARDIOMETABOLIC RISK IN CURRENT AND FUTURE GENERATIONS, UNDERSCORING THE IMPORTANCE OF THE EARLY LIFE PERIOD. SECOND, THERE IS GROWING EVIDENCE THAT INFECTION MAY LEAD TO BOTH A LOCAL AND SYSTEMIC INFLAMMATORY STATE. IN THE CONTEXT OF MATERNAL- FETAL DYAD, MATERNAL INFECTION WAS FOUND TO BE ASSOCIATED WITH INCREASED LEVELS OF PRO- AND ANTI-INFLAMMATORY CYTOKINE LEVELS IN CORD BLOOD, INDEPENDENT OF VERTICAL PATHOGEN TRANSMISSION. TO DATE, LITTLE IS KNOWN ABOUT METABOLIC-IMMUNE SYSTEM CROSSTALK IN EARLY LIFE AND HEALTH IMPLICATIONS. THE OVERARCHING GOAL OF THIS PROJECT IS TO INVESTIGATE THE ASSOCIATION OF THE EARLY LIFE ANTIBODY PROFILE TO A BROAD ARRAY OF PATHOGENIC AND COMMENSAL MICROBES AND SYSTEMIC IMMUNOPROTEOMIC PROFILES IN THE INTERGENERATIONAL CARDIOMETABOLIC LINK. WE WILL ALSO EXPLORE MICRONUTRIENT STATUS AS A PROTECTIVE FACTOR. SPECIFICALLY, WE AIM TO 1) IDENTIFY EARLY LIFE IMMUNE RESPONSE SIGNATURES OF LONG-TERM CARDIOMETABOLIC OUTCOMES; 2) EXAMINE THE ROLE OF EARLY LIFE IMMUNE RESPONSES IN THE INTERGENERATIONAL CARDIOMETABOLIC LINK; AND 3) EXPLORE THE INTERPLAY OF EARLY LIFE MICRONUTRIENT STATUS AND IMMUNE RESPONSES ON THE INTERGENERATIONAL LINK OF CARDIOMETABOLIC OUTCOMES. WE WILL LEVERAGE THE RICH RESOURCES OF THE BOSTON BIRTH COHORT (BBC), WITH ~3,500 MOTHER-CHILD PAIRS WHO WERE ENROLLED AT BIRTH AND FOLLOWED PROSPECTIVELY. WE HAVE SHOWN THAT THE BBC IS A HIGH-RISK POPULATION FOR ADVERSE CARDIOMETABOLIC OUTCOMES. A PARTICULARLY NOVEL ASPECT OF THIS STUDY IS THAT WE WILL LEVERAGE EXISTING ANTIBODY REPERTOIRE DATA GENERATED BY CUTTING-EDGE TECHNOLOGY (PHIP-SEQ) AND IMMUNOPROTEOMIC PROFILES GENERATED BY THE HIGH- THROUGHPUT OLINK PLATFORM AT TWO CRITICAL DEVELOPMENTAL WINDOWS: AT BIRTH (REFLECTING THE IN-UTERO STATE) AND AT AGE 1-2 YEARS (REFLECTING EARLY LIFE IMMUNE RESPONSE). SUCCESSFUL COMPLETION OF THIS STUDY WILL HELP TO DEEPEN OUR UNDERSTANDING OF THE IMMUNOLOGIC PATHWAYS UNDERLYING THE INTERGENERATIONAL CARDIOMETABOLIC LINK, REVEAL NOVEL BIOMARKERS AND TARGETS, AND LEAD TO A NEW PARADIGM FOR EARLY PREDICTION AND PREVENTION TO HALT OR REVERSE THE VICIOUS INTERGENERATIONAL CYCLE OF CARDIOMETABOLIC DISEASE.

Posted 9/17/24